查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1552896

細胞化驗分析市場規模、佔有率和趨勢分析報告：按產品/服務、應用、最終用途、地區和細分市場進行預測，2024-2030 年

Cell-based Assays Market Size, Share & Trends Analysis Report By Products & Services (Reagents, Assay Kits), By Application (Basic Research, Drug Discovery), By End Use, By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10個工作天內

價格
簡介目錄

細胞化驗分析市場的成長和趨勢：

Grand View Research, Inc.最新報告顯示，到2030年，全球細胞化驗分析市場規模預計將達到338億美元，2024年至2030年複合年成長率為8.8%。

對細胞化驗分析的需求不斷成長將推動市場的發展。基於細胞的檢測可以有效幫助加速並從而增強藥物開發。這將有助於確保治療藥物的穩定供應，以滿足產業需求。例如，這些測定用於主要候選藥物的選擇，並提供有關治療作用機制、藥物功效、安全性和毒性測試的有價值的資訊。這些檢測方法在藥物開發過程中的廣泛應用預計將推動需求。透過採用 CRISPR-Cas9 等多種技術，這些測定可以輕鬆解決基因組或細胞培養物中精確位置的特定標記的突變、敲入和敲除，從而已成為藥物發現不可或缺的一部分。

例如，Celprogen的人類胰臟細胞株表徵套件是一種基於細胞的ELISA試劑套件，用於測量細胞中的蛋白質濃度，以確定幹細胞的分化狀態，因而無需任何準備，可廣泛應用於藥物發現。同時，主要企業正在採取各種成長策略來擴大其管道、產品組合、產品線並滲透市場。例如，2022 年 7 月，Mission Bio, Inc. 透過其藥物檢測開發服務推出了一種檢測固態腫瘤的檢測方法，減少了表徵固態腫瘤的時間和成本，並改善了癌症藥物的開發過程。

此外，2022 年 4 月，Povile Sciences 將美國用於表觀遺傳學的 Chromatrap 晶片套件，以及我們在研究協會參展的用於高通量篩檢過程、細胞增殖和細胞生長的新檢測方法和新設計的細胞培養微孔盤。許多研究人員和臨床醫生正在尋找新的診斷效用的細胞基礎和新的治療方法，以有效對抗世界上日益增加的自體免疫、感染疾病和遺傳性疾病的負擔。的需求非常強烈。此外，COVID-19 大流行對研究活動的持續性和所進行的檢測類型都造成了重大干擾。

在美國境內，正在努力確保恢復研究活動，包括所有類型的細胞檢測。這些檢測也用於檢測 COVID-19 感染。例如，2020年5月，AcroBiosystem推出了流式細胞技術測定法來研究ACE2與S1蛋白/S1 RBD蛋白之間的結合。由於生物技術研究的增加、治療藥物研究的成長、主要參與者的存在以及癌症的高盛行率，北美在 2021 年將主導全球產業。由於生命科學研究需求不斷成長以及對基因層面疾病的了解不斷加深，亞太地區預計 2022 年至 2030 年複合年成長率最快。

細胞化驗分析市場報告亮點

  • 由於檢測套組可以為臨床醫生、研究人員和公眾提供實際好處，檢測套件產品領域在 2023 年佔據了最大的收益佔有率。
  • 現成的試劑套件和自我管理的診斷試劑套件如今越來越流行。
  • 預計藥物發現應用領域在預測期內將以良好的複合年成長率成長。
  • 這是由於藥物檢索數量的增加、FDA核准的增加、對新療法的需求增加以及遺傳疾病、癌症和感染疾病病例的增加。
  • 學術和研究最終用途領域預計在預測期內複合年成長率最快。
  • 這種成長是由於細胞化驗分析在診斷癌症、遺傳性疾病和感染疾病的效用不斷提高而推動的。

目錄

第1章調查方法與範圍

第 2 章執行摘要

第 3 章細胞化驗分析市場變數、趨勢和範圍

  • 市場介紹/系統展望
  • 市場規模及成長前景
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 細胞化驗分析市場分析工具
    • 波特的分析
    • PESTEL分析

第 4 章細胞化驗分析市場：按產品/服務進行估算和趨勢分析

  • 細分儀表板
  • 細胞化驗分析市場：2023 年和 2030 年產品與服務變化分析
  • 試劑
  • 檢測試劑套件
  • 微孔盤
  • 探針和標籤
  • 設備和軟體
  • 細胞株

第5章細胞化驗分析市場：依應用進行趨勢分析

  • 細分儀表板
  • 細胞化驗分析市場：應用變化分析，2023 年和 2030 年
  • 基礎調查
  • 藥物發現
  • 其他用途

第6章細胞化驗分析市場：依最終用途估算與趨勢分析

  • 細分儀表板
  • 細胞化驗分析市場：最終用戶變異分析，2023 年和 2030 年
  • 製藥和生物技術公司
  • 學術研究所
  • 受託研究機構（CRO）

第7章細胞化驗分析市場：區域估計和趨勢分析

  • 2023 年和 2030 年按地區分類的細胞化驗分析市場佔有率
  • 美國
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第8章 競爭格局

  • 主要市場參與企業的最新趨勢和影響分析
  • 公司分類
  • 企業熱力圖分析
  • 公司簡介
    • Bio-Rad Laboratories, Inc.
    • Corning Incorporated
    • Merck KGaA
    • Lonza Group AG
    • Charles River Laboratories
    • Becton, Dickinson and Company（BD）
    • Danaher Corporation
    • Promega Corporation
    • Thermo Fisher Scientific Inc.
    • F. Hoffmann-La Roche Ltd.（Roche Holdings AG）
    • Perkin Elmer Inc.
簡介目錄
Product Code: GVR-4-68039-984-4

Cell-based Assays Market Growth & Trends:

The global cell-based assays market size is expected to reach USD 33.8 billion by 2030, registering a CAGR of 8.8% from 2024 to 2030, according to a new report by Grand View Research, Inc. A rise in demand for cell-based assays will drive the market. Cell-based assays effectively aid in acceleration and thereby, enhancement of drug development. This helps therapeutic drugs to be supplied robustly to cater to the industry demand. For instance, these are used in lead candidate selection and provide invaluable information about therapeutic action mechanisms, drug efficacy, safety, and toxicity tests. Wide applications of these assays in drug development processes are expected to boost the demand. These assays are integral to the drug development process by adopting several technologies, such as CRISPR-Cas9, to allow easy resolution of mutations, knock-ins & knockouts of a specific marker at a precise location on the genome or a given culture of cells.

For instance, Celprogen's human pancreatic cancer cell line characterization kit is a cell-based ELISA kit that is used for the measurement of the concentration of a protein in cells for the determination of the differentiation status of stem cells, thereby eliminating the need to prepare cell lysates and is widely applicable for drug discovery. On the other hand, key players are undertaking various growth strategies to expand their pipelines, portfolios, and offerings to penetrate the market better. For instance, in July 2022, Mission Bio, Inc., launched assay for the detection of solid tumors through its pharma assay development services to aid the acceleration of the development process of cancer therapeutics by reducing the time & cost to characterize solid tumors.

Moreover, in April 2022, Porvair Sciences exhibited Chromatrap chip kits for epigenetics along with a new range of assay and newly designed cell culture microplates for high throughput screening process, cell growth, and proliferation at the American Association for Cancer Research. Many researchers and clinicians believe that there is a strong necessity for novel cell-based assays for their utility in diagnostics and to devise new therapeutic regimes to effectively combat the growing burden of autoimmune diseases, infectious diseases, and genetic disorders across the globe. Furthermore, the COVID?19 pandemic was substantially disruptive both to the continuance of research activities and the type of assays performed.

There are efforts across the U.S. to ensure re-igniting the research activities inclusive of all kinds of cell-based assays. These assays are used for the detection of COVID-19 infection as well. For instance, in May 2020, AcroBiosystem launched a flow cytometry assay to study the binding between ACE2 and S1 protein/S1 RBD protein, thus can be utilized for neutralizing antibody screening. North America dominated the global industry in 2021 owing to an increasing number of biotechnology research studies, growing research on therapeutic drugs, the presence of key players, and the high prevalence of cancer. Asia Pacific is expected to register the fastest CAGR from 2022 to 2030 due to the rising demand for research in life sciences and increased genetic level understanding of diseases.

Cell-based Assays Market Report Highlights:

  • The assay kits products segment accounted for the largest revenue share in 2023 due to the utilitarian benefits that a test kit could offer to clinicians, researchers, and the normal population.
  • Ready-to-use kits and self-administrable diagnostic kits are increasingly trending these days.
  • The drug discovery application segment is expected to grow at a lucrative CAGR over the forecast period.
  • This is due to a rise in the number of researches for therapeutic drug discovery, an increasing number of FDA approvals, and a rise in demand for novel therapeutic drugs coupled with increasing cases of genetic disorders, cancers, & infectious diseases.
  • The academic & research institutes end-use segment is expected to register the fastest CAGR over the forecast period.
  • The growth can be attributed to the greater utility of cell-based assays for the diagnosis of cancers, genetic disorders, and infectious diseases.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
  • 1.3. Research Methodology
    • 1.3.1. Information Procurement
    • 1.3.2. Information or Data Analysis
    • 1.3.3. Market Formulation & Data Visualization
    • 1.3.4. Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1. List of Data Sources

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Cell-based Assays Market Variables, Trends, & Scope

  • 3.1. Market Introduction/Lineage Outlook
  • 3.2. Market Size and Growth Prospects (USD Million)
  • 3.3. Market Dynamics
    • 3.3.1. Market Drivers Analysis
    • 3.3.2. Market Restraints Analysis
  • 3.4. Cell-based Assays Market Analysis Tools
    • 3.4.1. Porter's Analysis
      • 3.4.1.1. Bargaining power of the suppliers
      • 3.4.1.2. Bargaining power of the buyers
      • 3.4.1.3. Threats of substitution
      • 3.4.1.4. Threats from new entrants
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Economic and Social landscape
      • 3.4.2.3. Technological landscape
      • 3.4.2.4. Environmental landscape
      • 3.4.2.5. Legal landscape

Chapter 4. Cell-based Assays Market: Products & Services Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Cell-based Assays Market: Products & Services Movement Analysis, 2023 & 2030 (USD Million)
  • 4.3. Reagents
    • 4.3.1. Reagents Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.4. Assay Kits
    • 4.4.1. Assay Kits Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.4.2. Cell Growth Assays
      • 4.4.2.1. Cell Growth Assays Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.4.3. Reporter Gene Assays
      • 4.4.3.1. Reporter Gene Assays Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.4.4. Cell Death Assays
      • 4.4.4.1. Cell Death Assays Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.4.5. Second Messenger Assays
      • 4.4.5.1. Second Messenger Assays Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.5. Microplates
    • 4.5.1. Microplates Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.6. Probes & Labels
    • 4.6.1. Probes & Labels Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.7. Instruments & Software
    • 4.7.1. Instruments & Software Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.8. Cell Lines
    • 4.8.1. Cell Lines Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.8.2. Primary Cell Lines
      • 4.8.2.1. Primary Cell Lines Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.8.3. Stem Cell Lines
      • 4.8.3.1. Stem Cell Lines Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.8.4. Immortalized Cell Lines
      • 4.8.4.1. Immortalized Cell Lines Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Cell-based Assays Market: Application & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Cell-based Assays Market: Application Movement Analysis, 2023 & 2030 (USD Million)
  • 5.3. Basic Research
    • 5.3.1. Basic Research Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.4. Drug Discovery
    • 5.4.1. Drug Discovery Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.5. Other Applications
    • 5.5.1. Other Applications Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Cell-based Assays Market: End use Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Cell-based Assays Market: End-user Movement Analysis, 2023 & 2030 (USD Billion)
  • 6.3. Pharmaceutical & Biotechnology Companies
    • 6.3.1. Pharmaceutical & Biotechnology Companies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 6.4. Academic & Research Institutes
    • 6.4.1. Academic & Research Institutes Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 6.5. Contract Research Organizations (CROs)
    • 6.5.1. Contract Research Organizations (CROs)Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)

Chapter 7. Cell-based Assays Market: Regional Estimates & Trend Analysis

  • 7.1. Cell-based Assays Market Share, By Region, 2023 & 2030 (USD Billion)
  • 7.2. U.S.
    • 7.2.1. U.S. Cell-based Assays Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.2.2. U.S.
      • 7.2.2.1. U.S. Cell-based Assays Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.2.3. Canada
      • 7.2.3.1. Canada Cell-based Assays Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.2.4. Mexico
      • 7.2.4.1. Mexico Cell-based Assays Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.3. Europe
    • 7.3.1. Europe Cell-based Assays Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.3.2. UK
      • 7.3.2.1. UK Cell-based Assays Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.3.3. Germany
      • 7.3.3.1. Germany Cell-based Assays Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.3.4. France
      • 7.3.4.1. France Cell-based Assays Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.3.5. Italy
      • 7.3.5.1. Italy Cell-based Assays Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.3.6. Spain
      • 7.3.6.1. Spain Cell-based Assays Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.3.7. Denmark
      • 7.3.7.1. Denmark Cell-based Assays Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.3.8. Sweden
      • 7.3.8.1. Sweden Cell-based Assays Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.3.9. Norway
      • 7.3.9.1. Norway Cell-based Assays Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.4. Asia Pacific
    • 7.4.1. Asia Pacific Cell-based Assays Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.4.2. Japan
      • 7.4.2.1. Japan Cell-based Assays Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.4.3. China
      • 7.4.3.1. China Cell-based Assays Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.4.4. India
      • 7.4.4.1. India Cell-based Assays Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.4.5. Australia
      • 7.4.5.1. Australia Cell-based Assays Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.4.6. South Korea
      • 7.4.6.1. South Korea Cell-based Assays Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.4.7. Thailand
      • 7.4.7.1. Thailand Cell-based Assays Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.5. Latin America
    • 7.5.1. Latin America Cell-based Assays Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.5.2. Brazil
      • 7.5.2.1. Brazil Cell-based Assays Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.5.3. Argentina
      • 7.5.3.1. Argentina Cell-based Assays Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.6. Middle East and Africa
    • 7.6.1. Middle East and Africa Cell-based Assays Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.6.2. South Africa
      • 7.6.2.1. South Africa Cell-based Assays Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.6.3. Saudi Arabia
      • 7.6.3.1. Saudi Arabia Cell-based Assays Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.6.4. UAE
      • 7.6.4.1. UAE Cell-based Assays Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.6.5. Kuwait
      • 7.6.5.1. Kuwait Cell-based Assays Market Estimates and Forecasts, 2018 - 2030 (USD Billion)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis by Key Market Participants
  • 8.2. Company Categorization
  • 8.3. Company Heat Map Analysis
  • 8.4. Company Profiles
    • 8.4.1. Bio-Rad Laboratories, Inc.
      • 8.4.1.1. Participant's Overview
      • 8.4.1.2. Financial Performance
      • 8.4.1.3. Product Benchmarking
      • 8.4.1.4. Recent Developments/Strategic Initiatives
    • 8.4.2. Corning Incorporated
      • 8.4.2.1. Participant's Overview
      • 8.4.2.2. Financial Performance
      • 8.4.2.3. Product Benchmarking
      • 8.4.2.4. Recent Developments/Strategic Initiatives
    • 8.4.3. Merck KGaA
      • 8.4.3.1. Participant's Overview
      • 8.4.3.2. Financial Performance
      • 8.4.3.3. Product Benchmarking
      • 8.4.3.4. Recent Developments/Strategic Initiatives
    • 8.4.4. Lonza Group AG
      • 8.4.4.1. Participant's Overview
      • 8.4.4.2. Financial Performance
      • 8.4.4.3. Product Benchmarking
      • 8.4.4.4. Recent Developments/Strategic Initiatives
    • 8.4.5. Charles River Laboratories
      • 8.4.5.1. Participant's Overview
      • 8.4.5.2. Financial Performance
      • 8.4.5.3. Product Benchmarking
      • 8.4.5.4. Recent Developments/Strategic Initiatives
    • 8.4.6. Becton, Dickinson and Company (BD)
      • 8.4.6.1. Participant's Overview
      • 8.4.6.2. Financial Performance
      • 8.4.6.3. Product Benchmarking
      • 8.4.6.4. Recent Developments/Strategic Initiatives
    • 8.4.7. Danaher Corporation
      • 8.4.7.1. Participant's Overview
      • 8.4.7.2. Financial Performance
      • 8.4.7.3. Product Benchmarking
      • 8.4.7.4. Recent Developments/Strategic Initiatives
    • 8.4.8. Promega Corporation
      • 8.4.8.1. Participant's Overview
      • 8.4.8.2. Financial Performance
      • 8.4.8.3. Product Benchmarking
      • 8.4.8.4. Recent Developments/Strategic Initiatives
    • 8.4.9. Thermo Fisher Scientific Inc.
      • 8.4.9.1. Participant's Overview
      • 8.4.9.2. Financial Performance
      • 8.4.9.3. Product Benchmarking
      • 8.4.9.4. Recent Developments/Strategic Initiatives
    • 8.4.10. F. Hoffmann-La Roche Ltd. (Roche Holdings AG)
      • 8.4.10.1. Participant's Overview
      • 8.4.10.2. Financial Performance
      • 8.4.10.3. Product Benchmarking
      • 8.4.10.4. Recent Developments/Strategic Initiatives
    • 8.4.11. Perkin Elmer Inc.
      • 8.4.11.1. Participant's Overview
      • 8.4.11.2. Financial Performance
      • 8.4.11.3. Product Benchmarking
      • 8.4.11.4. Recent Developments/Strategic Initiatives